Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Management of antiangiogenic therapy-induced hypertension.

Literature DB >> 22851729

Management of antiangiogenic therapy-induced hypertension.

Nilka de Jesus-Gonzalez¹, Emily Robinson, Javid Moslehi, Benjamin D Humphreys.

Abstract

Entities: Chemical Disease Gene Species

Mesh：

Substances：

Year: 2012 PMID： 22851729 PMCID： PMC3421063 DOI： 10.1161/HYPERTENSIONAHA.112.196774

Source DB: PubMed Journal: Hypertension ISSN： 0194-911X Impact factor: 10.190

× No keyword cloud information.

67 in total

1. Treatment of arterial hypertension (AHT) associated with angiogenesis inhibitors.

Authors: L Y Dirix; H Maes; C Sweldens
Journal: Ann Oncol Date: 2007-06 Impact factor: 32.976

2. Hypertension as a predictive factor of Sunitinib activity.

Authors: O Rixe; B Billemont; H Izzedine
Journal: Ann Oncol Date: 2007-06 Impact factor: 32.976

3. Sorafenib in advanced clear-cell renal-cell carcinoma.

Authors: Bernard Escudier; Tim Eisen; Walter M Stadler; Cezary Szczylik; Stéphane Oudard; Michael Siebels; Sylvie Negrier; Christine Chevreau; Ewa Solska; Apurva A Desai; Frédéric Rolland; Tomasz Demkow; Thomas E Hutson; Martin Gore; Scott Freeman; Brian Schwartz; Minghua Shan; Ronit Simantov; Ronald M Bukowski
Journal: N Engl J Med Date: 2007-01-11 Impact factor: 91.245

4. Bevacizumab increases the risk of arterial ischemia: a large study in cancer patients with a focus on different subgroup outcomes.

Authors: F A B Schutz; Y Je; G R Azzi; P L Nguyen; T K Choueiri
Journal: Ann Oncol Date: 2010-11-29 Impact factor: 32.976

5. Diastolic blood pressure as a biomarker of axitinib efficacy in solid tumors.

Authors: Brian I Rini; Joan H Schiller; John P Fruehauf; Ezra E W Cohen; Jamal C Tarazi; Brad Rosbrook; Angel H Bair; Alejandro D Ricart; Anthony J Olszanski; Kristen J Letrent; Sinil Kim; Olivier Rixe
Journal: Clin Cancer Res Date: 2011-04-29 Impact factor: 12.531

Review 6. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis.

Authors: Xiaolei Zhu; Shenhong Wu; William L Dahut; Chirag R Parikh
Journal: Am J Kidney Dis Date: 2007-02 Impact factor: 8.860

Review 7. Angiogenesis inhibitor therapies: focus on kidney toxicity and hypertension.

Authors: Hassane Izzedine; Olivier Rixe; Bertrand Billemont; Alain Baumelou; Gilbert Deray
Journal: Am J Kidney Dis Date: 2007-08 Impact factor: 8.860

Review 8. The importance of endothelin-1 for vascular dysfunction in cardiovascular disease.

Authors: Felix Böhm; John Pernow
Journal: Cardiovasc Res Date: 2007-06-16 Impact factor: 10.787

9. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab.

Authors: Frank A Scappaticci; Jamey R Skillings; Scott N Holden; Hans-Peter Gerber; Kathy Miller; Fairooz Kabbinavar; Emily Bergsland; James Ngai; Eric Holmgren; Jiuzhou Wang; Herbert Hurwitz
Journal: J Natl Cancer Inst Date: 2007-08-08 Impact factor: 13.506

10. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib.

Authors: Brian I Rini; Darrel P Cohen; Dongrui R Lu; Isan Chen; Subramanian Hariharan; Martin E Gore; Robert A Figlin; Michael S Baum; Robert J Motzer
Journal: J Natl Cancer Inst Date: 2011-04-28 Impact factor: 13.506

35 in total

Review 1. Management of VEGF-Targeted Therapy-Induced Hypertension.

Authors: Stefano Caletti; Anna Paini; Maria Antonietta Coschignano; Carolina De Ciuceis; Matteo Nardin; Roberto Zulli; Maria Lorenza Muiesan; Massimo Salvetti; Damiano Rizzoni
Journal: Curr Hypertens Rep Date: 2018-06-29 Impact factor: 5.369

Review 2. Cardiovascular Complications of Targeted Therapies for Chronic Myeloid Leukemia.

Authors: Rongras Damrongwatanasuk; Michael G Fradley
Journal: Curr Treat Options Cardiovasc Med Date: 2017-04

3. Confusion of therapeutic approaches.

Authors: Philipp Ivanyi; Viktor Grünwald
Journal: Dtsch Arztebl Int Date: 2014-05-30 Impact factor: 5.594

Review 4. Use of Antihypertensive Drugs in Neoplastic Patients.

Authors: Damiano Rizzoni; Carolina De Ciuceis; Enzo Porteri; Claudia Agabiti-Rosei; Enrico Agabiti-Rosei
Journal: High Blood Press Cardiovasc Prev Date: 2017-03-30

5. Longitudinal Assessment of Vascular Function With Sunitinib in Patients With Metastatic Renal Cell Carcinoma.

Authors: Anna B Catino; Rebecca A Hubbard; Julio A Chirinos; Ray Townsend; Stephen Keefe; Naomi B Haas; Igor Puzanov; James C Fang; Neeraj Agarwal; David Hyman; Amanda M Smith; Mary Gordon; Theodore Plappert; Virginia Englefield; Vivek Narayan; Steven Ewer; Chantal ElAmm; Daniel Lenihan; Bonnie Ky
Journal: Circ Heart Fail Date: 2018-03 Impact factor: 8.790

Review 6. Exercise and Aerobic Fitness to Reduce Cancer-Related Cardiovascular Toxicity.

Authors: Umberto Campia; Ana Barac
Journal: Curr Treat Options Cardiovasc Med Date: 2016-07

7. Safety of bevacizumab in clinical practice for recurrent ovarian cancer: A retrospective cohort study.

Authors: Frédéric Selle; George Emile; Patricia Pautier; Irène Asmane; Daniele G Soares; Ahmed Khalil; Jerome Alexandre; Catherine Lhommé; Isabelle Ray-Coquard; Jean-Pierre Lotz; François Goldwasser; Youssef Tazi; Pierre Heudel; Eric Pujade-Lauraine; Sébastien Gouy; Olivier Tredan; Marie O Barbaza; Nora Ady-Vago; Coraline Dubot
Journal: Oncol Lett Date: 2016-01-26 Impact factor: 2.967